Merck agrees to acquire Acceleron for more than $11 billion in cash

  • Merck KGaA (NYSE:MRK) and Acceleron Pharma (NASDAQ:XLRN) have confirmed that the two companies have entered into an agreement under which Merck KGaA , through a subsidiary, will acquire Acceleron for $180 per share in cash, indicating a total equity value of nearly $11.5 billion.
  • The transaction is expected to close in Q4 2021. Both Merck KGaA (MRK) and Acceleron (XLRN) are trading flat in the pre-market.
  • Early this week, a potential acquisition of Acceleron (XLRN) drove its share price sharply higher.
  • The acquisition will complement Merck KGaA 's cardiovascular pipeline as Acceleron's lead candidate, sotatercept is currently undergoing Phase 3 studies for pulmonary arterial hypertension.
  • In reaction to a potential $11 billion deal, some Wall Street analysts argued that the premium implied in the transaction was inadequate.

    Over the current book year the total revenue from the company in Kenilworth will be 47.63 billion USD (consensus estimates). This is slightly lower than 2021's revenue of 47.99 billion USD.

    Historical revenues and results Merck KGaA & Co plus estimates 2021

    fundamantele data

    The analysts expect for 2021 a net profit of 14.42 billion USD. Most of the analysts anticipate on a profit per share of 5.67 USD. So the price/earnings-ratio equals 14.22.

    Huge dividend Merck KGaA & Co

    Per share the analysts are expecting a dividend of 2.57 USD per share. The dividend yield is then 3.19 percent. The average dividend yield of the pharmaceutical companies equals a moderate 1.37 percent.

    Merck KGaA & Co's market value equals around 204.72 billion . 9

    On Friday the stock closed at 80.63 USD.

    Historical stock prices Merck KGaA & Co

    stock analysis merck&co

    ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
    news@valuespectrum.com

    Copyright analist.nl B.V.
    All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.